The landmark Premature Infant in Need of Transfusion (PINT) trial [9] and the findings of Chen et al. [10] have convinced neonatologists to transfuse at lower Hb thresholds by indicating a lesser requirement for PRBCTs without compromising any neonatal morbidities, i.e., severe intraventricular hemorrhage, retinopathy of prematurity, or chronic lung disease. Here, GSTM1 is linked to Intraventricular hemorrhage.